WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

Author: Lekha Gupta | February 16, 2025 09:45am

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?

1. WeRide Inc. (NASDAQ:WRD) shares rocketed 97.62% after NVIDIA Corporation (NASDAQ:NVDA) disclosed a stake of 1.74 million shares in a 13F filing.
2. GDS Holdings Limited (NASDAQ:GDS) stock escalated 43.45%, probably after President Trump had reportedly postponed tariffs on packages under $800 from China. Additionally, optimism towards China’s DeepSeek AI model has also lifted stocks recently.
3. SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares jumped 42.58% after announcing Merck KGaA (OTC:MKGAF) (OTC:MKKGY) is in advanced discussions to acquire the company.
4. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares increased 40.59%.
5. Sable Offshore Corp. (NYSE:SOC) stock upped 39.09%.
6. GeneDx Holdings Corp. (NASDAQ:WGS) shares rose 28.23%  after the company announced UltraRapid Whole Genome Sequencing, which will deliver actionable results within 48 hours.
7. VNET Group, Inc. (NASDAQ:VNET) stock upped 28.22%, probably amid a possible rebound after falling last week due to AI competition concerns related to China’s DeepSeek AI model.
8. Insperity, Inc. (NYSE:NSP) stock increased 25.99% after the company reported better-than-expected fourth-quarter results.
9. CRISPR Therapeutics AG (NASDAQ:CRSP) stock grew 25.21% after the company reported better-than-expected fourth-quarter financial results. Several analysts raised the price forecast on the stock.
10. Axsome Therapeutics, Inc. (NASDAQ:AXSM) stock grew 24.01% after the company reached a settlement agreement with Teva Pharmaceutical (NYSE:TEVA), resolving all patent litigation related to its Auvelity product. Several analysts raised the price forecast on the stock.

Photo via WeRide

Posted In: AXSM CRSP GDS MKGAF MKKGY NSP NVDA RXRX SOC SWTX TEVA VNET WGS WRD